LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

Do‐Youn Oh ,Lucjan Wyrwicz ,Moïshe Liberman ,Sofia Oliveira ,Josep Tabernero ,Takeshi Omori ,Marcelo Garrido ,Woo Jin Hyung ,Zev A Wainberg ,John F Kurland ,Daniela Molena ,Yelena Y Janjigian ,Markus Moehler ,Victor Castro ,Ioannis Xynos ,S-E Al-Batran,Mehmet Bilici ,Helen Mann ,Kei Muro ,Éric Van Cutsem

doi:10.1016/j.annonc.2023.10.074

LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

Do‐Youn Oh , Lucjan Wyrwicz + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2023.10.074

Copy DOI

#Gastroesophageal Junction Cancer #Resectable Gastric Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

Full Text